Drugs / idronoxil
idronoxil
also known as
phenoxodiol · NOX66 · PXD · Dehydroequol · Idronoxil component of nox-66 · Idronoxil component of nox66 suppository · Idronoxilo · NV-06
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03780465 | Mar 2019 | — | Noxopharm Limited | Withdrawn | No outcome recorded |
| Phase 1 | NCT03041285 | Aug 2017 → Sep 2019 | castration-resistant prostate carcinoma | Royal North Shore Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT00303888 | May 2006 → Aug 2009 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Yale University | Terminated | No outcome recorded |
| Phase 1 | NCT00022295 | Aug 2001 → Oct 2007 | cancer of unknown primary site | Kazia Therapeutics Limited | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04957290 | Oct 2021 → May 2023 | castration-resistant prostate carcinoma | Noxopharm Limited | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00091377 | Aug 2004 → Dec 2007 | fallopian tube carcinoma, ovarian carcinoma, peritoneal carcinoma | MEI Pharma, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00557037 | Nov 2007 → Nov 2009 | prostate cancer | MEI Pharma, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00382811 | Oct 2006 → Apr 2009 | fallopian tube cancer, ovarian cancer, peritoneal neoplasm | MEI Pharma, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 35
| Date | Issuer | Release |
|---|---|---|
| 2023-05-26 | Noxopharm Limited | Results IONIC Trial Abstract Published at ASCO noxopharm.com ↗
Sydney, 26 May 2023: Innovative biotech company Noxopharm Limited (ASX:NOX) announces preliminary data from the IONIC investigator-initiated pilot Phase 1 trial of oncology drug candidate Veyonda® has been published online in the form of an abstract at the American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago from 2-6 June 2023. |
| 2022-05-27 | Noxopharm Limited | Results Veyonda Abstract Published at ASCO Annual Meeting 2022 noxopharm.com ↗
The findings confirmed that using idronoxil in combination with cisplatin could change the tumour environment, allowing a larger number of immune cells to infiltrate the tumours compared to the control. |
| 2021-08-23 | Noxopharm Limited | Results NOXCOVID Program to Expand After Positive Phase 1 Results noxopharm.com ↗
Noxopharm Limited (ASX:NOX) releases preliminary top line data of its NOXCOVID phase 1 clinical trial. |
| 2021-08-23 | Noxopharm Limited | Results Pre-clinical Data Supports a Role for Veyonda in COVID-19 noxopharm.com ↗
That discovery is the identification of the enzyme, TANK-binding kinase 1 (TBK1), as the molecular target of idronoxil in terms of its anti-inflammatory properties. |
| 2021-08-05 | Noxopharm Limited | Results Veyonda Survival Advantage in LuPSMA Therapy Confirmed noxopharm.com ↗
However, the addition of Veyonda had an even more profound anti-cancer effect, going beyond blocking tumour growth into full regression of most of the tumours, to the extent that median overall survival could not be determined. |
| 2021-06-29 | Noxopharm Limited | Regulatory Noxopharm Secures Key European Patent Allowance for Veyonda noxopharm.com ↗
Noxopharm Limited (ASX:NOX) is pleased to announce that the European Patent Office (EPO) has issued a formal Notice of Allowance of claims for Patent Application No. 17778482.4, indicating an intention to move to patent grant. |
| 2021-04-30 | Noxopharm Limited | Results Publications Positive Review of Veyonda in Chemotherapy noxopharm.com ↗
Noxopharm Limited (ASX:NOX) is pleased to announce that the results from its CEP-1 study (Chemotherapy Enhancement Program) have been published in the peer-reviewed journal Current Therapeutic Research. |
| 2021-02-15 | Noxopharm Limited | Results LuPIN Survival Outcome Confirmed by Conference Presentation noxopharm.com ↗
Drug combination NOX66 (Veyonda) and 177lutetium-PSMA-617 delivers high response rates in heavily pre-treated men with end-stage prostate cancer |
| 2020-11-18 | Noxopharm Limited | Results Further Independent Support for Veyonda as a Major I-O Drug noxopharm.com ↗
Idronoxil (IDX), the active ingredient in Veyonda, confirmed as promoting migration of active immune cells into tumour structures |
| 2020-09-01 | Noxopharm Limited | Regulatory Veyonda COVID-19 Study Approved For Immediate Start noxopharm.com ↗
Following review by expert panels, official approval has been granted for immediate commencement of the Phase 1 NOXCOVID-1 study. |
| 2020-07-20 | Noxopharm Limited | Results Data Shows Idronoxil Holds Key to Problem of COLD Cancers noxopharm.com ↗
Important pre-clinical data from two independent research groups confirms that idronoxil (IDX), the active ingredient in Veyonda, achieves a major goal in restoring cancer-fighting immune function within ‘COLD’ micro-tumours by converting them to ‘HOT’ . |
| 2020-06-01 | Noxopharm Limited | Results ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer noxopharm.com ↗
Noxopharm (ASX: NOX) today reports on the public release at a global oncology conference of 2 sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment of end-stage cancer. |
| 2020-05-19 | Noxopharm Limited | Regulatory FDA allows Veyonda Pre-IND Submission for COVID-19 noxopharm.com ↗
Noxopharm (ASX:NOX) today announces that on advice from the U.S. Food and Drug Administration (FDA), the Company has lodged a pre-Investigational New Drug (pre-IND) submission for a clinical trial of Veyonda® in patients with SARS-CoV-2 (COVID-19) infection. |
| 2020-05-14 | Noxopharm Limited | Results Noxopharm ASCO Abstracts Live noxopharm.com ↗
Collaborators at Hong Kong University studying the immuno -oncology properties of idronoxil, hav e confirmed in pre -clinical studies that idronoxil promotes infiltration of tumours by immune cells. |
| 2020-04-30 | Noxopharm Limited | Results Abscopal Responses Achieved in Prostate Cancer noxopharm.com ↗
Noxopharm (ASX:NOX) today releases details of the radiographic review of its DARRT-1 clinical study and is pleased to report that it shows a major benefit from a combination of Veyonda® and low-dose radiotherapy. |
| 2020-03-17 | Noxopharm Limited | Regulatory Veyonda Awarded First Allowed Patent Application noxopharm.com ↗
Noxopharm (NOX:ASX) announces that Australian patent application No. 2016401508 has been allowed by the Australian Patent Office. |
| 2020-02-21 | Noxopharm Limited | Regulatory FDA grants IND approval to Veyonda noxopharm.com ↗
Noxopharm (NOX:ASX) announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas. |
| 2020-02-14 | Noxopharm Limited | Results Pronounced survival benefit in LuPIN interim trial data noxopharm.com ↗
The data presented at ASCO GU today reports the interim results from the first 32 patients receiving the combination. |
| 2020-01-29 | Noxopharm Limited | Results Noxopharm Non-Deal Roadshow Presentation noxopharm.com ↗
In summary, combination therapy of Veyonda® and 177Lu-PSMA-617 shows benefits to patients well above that achieved with 177Lu-PSMA-617 therapy alone and underscores the Company’s confidence in Veyonda® eventually becoming a standard drug in the management of prostate cancer |
| 2019-12-02 | Noxopharm Limited | Results Positive DARRT-1 Data in Late-Stage Prostate Cancer noxopharm.com ↗
This is exciting data that validates our confidence in the future of the NOX66 DARRT treatment regimen. |
| 2019-11-12 | Noxopharm Limited | Results LuPIN Data Being Presented To Conference noxopharm.com ↗
Within the limits of comparing data sets from different studies, combination therapy was superior to monotherapy in terms of: |
| 2019-10-30 | Noxopharm Limited | Results Noxopharm October 2019 Newsletter noxopharm.com ↗
The leading article comments on the interim data from the DARRT-1 clinical study showing that a combination of Veyonda and low -dose radiotherapy is stopping the growth of late -stage prostate cancer and providing durable pain relief in a high proportion of men. |
| 2019-09-30 | Noxopharm Limited | Results Further Review Shows Major Clinical Benefits from Veyonda noxopharm.com ↗ |
| 2019-08-28 | Noxopharm Limited | Results More Evidence that Veyonda Enhances RT in Prostate Cancer noxopharm.com ↗
Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on its proprietary treatment Veyonda combined with radiotherapy which resulted in reductions in tumour size; reductions in pain for 45% of the men; and reductions in PSA levels for 55% of these men. |
| 2019-08-21 | Noxopharm Limited | Results Pre-Clinical Evidence Confirms Veyonda Abscopal Effect noxopharm.com ↗
Pre-clinical studies now confirming this effect |
| 2019-06-26 | Noxopharm Limited | Results Conference Hears of Positive Interim Data from LuPIN Trial noxopharm.com ↗
Clinical data shows combining Veyonda with radiopharmaceutical, 177Lu-PSMA-617, is well tolerated and with early signals of anti-cancer activity |
| 2019-05-02 | Noxopharm Limited | Results DARRT Treatment Has Lasting Disease Control at Six Months noxopharm.com ↗ |
| 2019-04-16 | Noxopharm Limited | Results Idronoxil Confirmed as New Immuno-Oncology Drug noxopharm.com ↗
The studies confirm that IDX activates cells associated with both the innate and adaptive immune systems, increasing functional natural killer (NK) cells and CD4+ (T-helper) cell numbers. |
| 2019-04-10 | Noxopharm Limited | Results Veyonda Chemotherapy Enhancement Program to be Expanded noxopharm.com ↗
Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancers |
| 2019-02-06 | Noxopharm Limited | Results Veyonda and Radiotherapy Delivers Clinical Benefits noxopharm.com ↗
combining Veyonda with low-dose radiotherapy applied to a single metastasis (lesion) is able to produce an anti-cancer response in both the irradiated and non-irradiated lesions as evidenced by PSA response, pain reduction, and/or tumour measurements |
| 2018-12-11 | Noxopharm Limited | Results DARRT-1 study advancing on basis of positive clinical data noxopharm.com ↗
Signs of positive clinical responses with the two highest dosages of Veyonda (800 and 1200 mg) included partial responses, declines in PSA greater than 50%, and material reductions in pain scores. |
| 2018-11-29 | Noxopharm Limited | Results NOX announces Positive Data from CEP-1 Study of Veyonda noxopharm.com ↗
Noxopharm (ASX: NOX) announces the final results from its Phase 1b CEP-1 trial evaluating its lead immuno-oncology/radio-enhancer drug candidate, Veyonda, in combination with low-dose carboplatin in late-stage metastatic solid cancers. |
| 2018-07-05 | Noxopharm Limited | Results Pre-Clinical data confirms Radio-Enhancing potential noxopharm.com ↗
Idronoxil was able to kill these cancer cells on its own, but more importantly, sensitised the cells to radiation, leading to a significantly higher level of death of cancer cells using a constant dosage of radiation. |
| 2018-05-22 | Noxopharm Limited | Results NOX to present at American Society of Clinical Oncology noxopharm.com ↗
Given that this is the first time that idronoxil has been administered to humans in a form we believe capable of preserving its potency, the lack of any serious side-effects is a key milestone for this drug candidate. |
| 2018-03-21 | Noxopharm Limited | Results Evidence of Abscopal Responses in Patients noxopharm.com ↗
Abscopal responses obtained in both patients |
All press releases naming this drug 40 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Idronoxil | “idronoxil when rectally administered as a suppository (NOX66)” NCT04957290 ↗ |
| Known as | Dehydroequol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1957038 ↗ |
| Known as | Idronoxil component of nox-66 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1957038 ↗ |
| Known as | Idronoxil component of nox66 suppository | ChEMBL registry synonym — accepted as the source's own label CHEMBL1957038 ↗ |
| Known as | Idronoxilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1957038 ↗ |
| Known as | NOX66 | “idronoxil when rectally administered as a suppository (NOX66)” NCT04957290 ↗1“idronoxil (NOX66) suppository” NCT03041285 ↗ |
| Known as | NV-06 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1957038 ↗ |
| Known as | phenoxodiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00382811 ↗ |
| Known as | PXD | “the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential” PMID 24318743 ↗ Dec 20131“Patients will receive Phenoxodiol (PXD) 400 mg every 8 hours daily for 28 consecutive days (1 cycle).” NCT00557037 ↗ |
| Modality | Other / unclassified | “a novel biomodulator” PMID 24318743 ↗ Dec 2013 |
| Modality | Small molecule | — CHEMBL1957038 ↗ |
| Route | Intravenous | “intravenous phenoxodiol” PMID 21412168 ↗ May 2011 |